Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

VJVirtual | Prognostic value of the SPOP mutant genomic subclass in prostate cancer

Eric Klein • 3 Apr 2020
Genitourinary Cancer Prostate Cancer

Eric Klein, MD, Glickman Urology & Kidney Institute, Cleveland, OH, reviews a publication he co-authored on the prognostic value of SPOP mutant genomic subclass in prostate cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Eric Klein

2:41
MCED: reducing cancer mortality
Eric Klein • 18 Oct 2022
2:09
IsoPSA: blood-based assay for improved detection of prostate cancer
Eric Klein • 18 Oct 2022
1:14
Polygenic risk scores for the early detection of prostate cancer
Eric Klein • 18 Oct 2022
2:57
Role of genomic profiling in the management of intermediate-risk prostate cancer
Eric Klein • 18 Oct 2022

Related Videos

2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
3:07
Serum thymidine kinase 1 as a predicative biomarker in prostate cancer
Teemu Murtola • 9 Apr 2024
0:57
Real-world outcomes of 177Lu-PSMA-617 in mCRPC
Hannah McManus • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals